Thomas Garner serves as our Chief Commercial Officer, leading Acadia’s commercial strategy and operations globally. Mr. Garner brings more than 25 years of pharmaceutical and biotechnology experience, with a strong track record of successfully launching and expanding brands in neuroscience, rare disease, and other complex therapeutic areas. View All Management Team
Before joining Acadia, Mr. Garner was Senior Vice President and Chief Commercial Officer at Lexicon Pharmaceuticals, where he oversaw the relaunch of INPEFA® (sotagliflozin) and guided commercial and business development strategies for the company’s portfolio. Previously, he spent more than two decades at Bristol Myers Squibb (BMS) in leadership roles spanning sales, marketing, and global commercialization. During his tenure at BMS, Mr. Garner served as Senior Vice President and Head of the U.S. Cardiovascular and Established Brands business unit, with responsibility for multiple high-revenue brands including ELIQUIS® (apixaban) and CAMZYOS® (mavacamten). Earlier in his career at BMS, he led the global launches for OPDIVO® (nivolumab) and YERVOY® (ipilimumab) in first-line lung cancer, and head & neck cancers. Prior to relocating to the United States in 2015, Mr. Garner was the general manager for BMS Denmark, and held various commercial roles of increasing seniority at BMS UK. Before joining BMS in 2002, he held positions at Eli Lilly, Boehringer Ingelheim, and Maco Pharma.
Mr. Garner holds a BSc (Honors) degree from the Royal Agricultural University, Cirencester in the United Kingdom and a certification in General Management from INSEAD at Fontainebleau, France.